Koivisto P - Search Results

1

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: koivisto p. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

2

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: koivisto p. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

3

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: koivisto p. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

4

Androgen receptor CAG polymorphism and prostate cancer risk.

Mononen N, Ikonen T, Autio V, Rökman A, Matikainen MP, Tammela TL, Kallioniemi OP, Koivisto PA, Schleutker J. Mononen N, et al. Among authors: koivisto pa. Hum Genet. 2002 Aug;111(2):166-71. doi: 10.1007/s00439-002-0776-5. Epub 2002 Jul 3. Hum Genet. 2002. PMID: 12189490

5

Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer.

Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Koivisto PA, et al. J Urol. 2004 Jan;171(1):431-3. doi: 10.1097/01.ju.0000089774.99728.ef. J Urol. 2004. PMID: 14665948

6

Kruppel-like factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer.

Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Koivisto PA, et al. J Urol. 2004 Aug;172(2):506-7. doi: 10.1097/01.ju.0000129242.88182.e1. J Urol. 2004. PMID: 15247715

7

Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy.

Palmberg C, Rantala I, Tammela TL, Helin H, Koivisto PA. Palmberg C, et al. Among authors: koivisto pa. Oncol Rep. 2000 Sep-Oct;7(5):1141-4. doi: 10.3892/or.7.5.1141. Oncol Rep. 2000. PMID: 10948353

8

Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene.

Mononen N, Syrjäkoski K, Matikainen M, Tammela TL, Schleutker J, Kallioniemi OP, Trapman J, Koivisto PA. Mononen N, et al. Among authors: koivisto pa. Cancer Res. 2000 Nov 15;60(22):6479-81. Cancer Res. 2000. PMID: 11103816

9

Chromosomal changes in locally recurrent, hormone-refractory prostate carcinomas by karyotyping and comparative genomic hybridization.

Haapala K, Rökman A, Palmberg C, Hyytinen ER, Laurila M, Tammela TL, Koivisto PA. Haapala K, et al. Among authors: koivisto pa. Cancer Genet Cytogenet. 2001 Nov;131(1):74-8. doi: 10.1016/s0165-4608(01)00491-5. Cancer Genet Cytogenet. 2001. PMID: 11734323

10

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP. Koivisto P, et al. Am J Pathol. 1995 Dec;147(6):1608-14. Am J Pathol. 1995. PMID: 7495286 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters